Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-15 00:24 | 2025-05-12 | BBIO | BridgeBio Pharma, Inc. | KKR Genetic Disorder L.P. | 10% owner | SELL | $34.20 | 6,000,000 | $205,200,000 | 13,260,971 |
| 2025-05-14 23:11 | 2025-05-14 | CRVO | CervoMed Inc. | ELDER WILLIAM ROBERT | Officer | BUY | $8.46 | 4,233 | $35,811 | 5,500 |
| 2025-05-14 03:04 | 2025-05-09 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | Officer | BUY | $104.06 | 1,500 | $156,090 | 27,932 |
| 2025-05-14 01:36 | 2025-05-12 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% owner | BUY | $8.11 | 21,167 | $171,664 | 2,942,761 |
| 2025-05-14 04:11 | 2025-05-12 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | SELL | $41.48 | 30,000 | $1,244,454 | 594,324 |
| 2025-05-13 23:42 | 2025-05-12 | AMRX | Amneal Pharmaceuticals Inc. | Kiely John | Director | SELL | $7.59 | 50,000 | $379,500 | 257,433 |
| 2025-05-13 23:48 | 2025-05-09 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $29.53 | 100,000 | $2,953,310 | 479,851 |
| 2025-05-13 23:48 | 2025-05-09 | ZLAB | Zai Lab Ltd | Morrison Scott W | Director | SELL | $30.05 | 23,799 | $715,086 | 23,702 |
| 2025-05-13 23:11 | 2025-05-09 | LFVN | Lifevantage Corp | Mauro Garry Paul | Director | BUY | $12.25 | 2,150 | $26,338 | 6,598 |
| 2025-05-14 02:03 | 2025-05-09 | BMY | BRISTOL MYERS SQUIBB CO | Hickey Benjamin | Officer | SELL | $38.01 | 97 | $3,702 | 0 |
| 2025-05-14 03:05 | 2025-05-09 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | Director, Officer | BUY | $105.20 | 9,510 | $1,000,457 | 161,234 |
| 2025-05-13 23:11 | 2025-05-09 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | BUY | $13.60 | 6,300 | $85,691 | 6,300 |
| 2025-05-13 23:13 | 2025-05-09 | PHAT | Phathom Pharmaceuticals, Inc. | Topper James N | Director | BUY | $3.17 | 48,203 | $152,914 | 48,203 |
| 2025-05-13 23:20 | 2025-05-09 | GERN | GERON CORP | LAWLIS V BRYAN | Director | BUY | $1.18 | 13,300 | $15,667 | 13,300 |
| 2025-05-14 01:51 | 2025-05-09 | JAZZ | Jazz Pharmaceuticals plc | Mulligan Seamus | Director | BUY | $98.34 | 101,621 | $9,993,084 | 101,621 |
| 2025-05-14 00:05 | 2025-05-12 | GNLX | GENELUX Corp | Ryder Sean | Officer | SELL | $2.92 | 4,475 | $13,067 | 47,621 |
| 2025-05-14 00:05 | 2025-05-12 | GNLX | GENELUX Corp | Zindrick Thomas | Director, Officer | SELL | $2.92 | 10,764 | $31,431 | 191,447 |
| 2025-05-14 00:05 | 2025-05-12 | GNLX | GENELUX Corp | Yu Yong | Officer | SELL | $2.92 | 5,579 | $16,291 | 47,640 |
| 2025-05-14 00:05 | 2025-05-12 | GNLX | GENELUX Corp | Cappello Joseph | Officer | SELL | $2.92 | 4,737 | $13,832 | 52,266 |
| 2025-05-14 00:05 | 2025-05-12 | GNLX | GENELUX Corp | Smalling Ralph | Officer | SELL | $2.92 | 1,259 | $3,676 | 34,760 |
| 2025-05-13 23:29 | 2025-05-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $62.20 | 400 | $24,880 | 79,745 |
| 2025-05-13 23:21 | 2025-05-09 | ANIP | Ani Pharmaceuticals Inc. | Shanmugam Muthusamy | Director, Officer | SELL | $76.83 | 700 | $53,781 | 631,920 |
| 2025-05-12 23:14 | 2025-05-08 | MAIA | MAIA Biotechnology, Inc. | Guerrero Ramiro | Director | BUY | $1.50 | 20,000 | $30,000 | 588,218 |
| 2025-05-12 23:12 | 2025-05-08 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.50 | 66,666 | $99,999 | 1,271,726 |
| 2025-05-12 16:25 | 2025-05-08 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% owner | BUY | $8.94 | 27,662 | $247,262 | 2,936,594 |
| 2025-05-12 23:00 | 2025-05-08 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Sabag Mark | Officer | SELL | $18.04 | 337,915 | $6,097,304 | 150,996 |
| 2025-05-13 03:50 | 2025-05-08 | OCUL | OCULAR THERAPEUTIX, INC | LINDSTROM RICHARD L MD | Director | BUY | $6.96 | 10,000 | $69,600 | 172,704 |
| 2025-05-12 23:15 | 2025-05-09 | BSPK | Bespoke Extracts, Inc. | FEINSOD MICHAEL | Director, Officer, 10% owner | BUY | $0.11 | 2,000 | $210 | 2,494,612 |
| 2025-05-12 23:05 | 2025-04-16 | ALNY | Alnylam Pharmaceuticals Inc. | Reitan Colleen F | Director | SELL | $232.86 | 36 | $8,383 | 0 |
| 2025-05-12 23:05 | 2024-08-29 | ALNY | Alnylam Pharmaceuticals Inc. | Reitan Colleen F | Director | BUY | $287.85 | 36 | $10,363 | 36 |
| 2025-05-13 04:30 | 2025-05-07 | PTN | PALATIN TECHNOLOGIES INC | DEVEER ROBERT K JR | Director | BUY | $0.10 | 100,000 | $10,180 | 138,065 |
| 2025-05-12 23:30 | 2025-05-09 | UTHR | UNITED THERAPEUTICS Corp | Thompson Tommy G | Director | OPT+S | $305.15 | 2,500 | $762,865 | 8,480 |
| 2025-05-13 01:58 | 2025-05-08 | LFCR | LIFECORE BIOMEDICAL, INC. DE | English Aron R. | 10% owner | SELL | $7.03 | 51,496 | $362,017 | 1,662,574 |
| 2025-05-10 00:32 | 2025-05-08 | HCWB | HCW Biologics Inc. | Wong Hing C | Director, Officer, 10% owner | BUY | $26.00 | 92,500 | $2,405,000 | 493,857 |
| 2025-05-10 00:30 | 2025-05-08 | HCWB | HCW Biologics Inc. | Byam Rebecca | Officer | BUY | $26.00 | 8,462 | $220,012 | 43,010 |
| 2025-05-10 00:29 | 2025-05-08 | HCWB | HCW Biologics Inc. | Flowers Lee | Officer | BUY | $26.00 | 962 | $25,012 | 5,720 |
| 2025-05-10 00:28 | 2025-05-08 | HCWB | HCW Biologics Inc. | Greene Rick S. | Director | BUY | $26.00 | 962 | $25,012 | 2,066 |
| 2025-05-10 00:33 | 2025-05-08 | HCWB | HCW Biologics Inc. | Winer Gary M | Director | BUY | $26.00 | 2,308 | $60,008 | 2,733 |
| 2025-05-10 01:53 | 2025-05-06 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% owner | BUY | $8.60 | 27,411 | $235,647 | 2,911,532 |
| 2025-05-10 04:30 | 2025-05-07 | OSTX | OS Therapies Inc | Auerbach Shalom | 10% owner | SELL | $2.00 | 82,000 | $163,918 | 2,664,199 |
| 2025-05-10 02:18 | 2025-05-07 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | Officer | OPT+S | $42.49 | 8,000 | $339,950 | 33,492 |
| 2025-05-10 02:45 | 2025-05-08 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $13.59 | 3,871 | $52,623 | 115,468 |
| 2025-05-10 00:01 | 2025-05-07 | KNSA | Kiniksa Pharmaceuticals International, plc | Paolini John F. | Officer | OPT+S | $27.00 | 200 | $5,400 | 57,403 |
| 2025-05-09 23:15 | 2025-05-08 | FULC | Fulcrum Therapeutics, Inc. | Tourangeau Greg | Officer | SELL | $5.06 | 498 | $2,520 | 14,062 |
| 2025-05-10 01:48 | 2025-05-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | Officer | SELL | $18.39 | 6,667 | $122,579 | 309,976 |
| 2025-05-10 00:32 | 2025-05-07 | KNSA | Kiniksa Pharmaceuticals International, plc | Patel Sanj K | Director, Officer | OPT+S | $27.04 | 8,095 | $218,866 | 96,674 |
| 2025-05-09 23:59 | 2025-05-07 | KNSA | Kiniksa Pharmaceuticals International, plc | Megna Michael R | Officer | OPT+S | $26.69 | 17,647 | $470,998 | 32,546 |
| 2025-05-10 00:31 | 2025-05-08 | HCWB | HCW Biologics Inc. | GARRETT SCOTT T | Director | BUY | $26.00 | 5,385 | $140,010 | 12,082 |
| 2025-05-10 00:05 | 2025-04-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Young Caroline | Director | BUY | $4.48 | 93 | $417 | 32,485 |
| 2025-05-10 00:04 | 2025-04-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Jones James | Director | BUY | $4.48 | 186 | $833 | 43,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.